FROM: U.S. FEDERAL TRADE COMMISSION
FTC Approves Final Order Barring Company from Making Unsubstantiated Claims Related to Products’ “Brain Training” Capabilities
Following a public comment period, the Federal Trade Commission has approved a final consent order barring Focus Education, the company that sold the Jungle Rangers “brain training” game, from making unsupported claims regarding Jungle Rangers’ ability to permanently improve children’s cognitive abilities, school performance, and behavior, including for children with attention deficit hyperactivity disorder (ADHD).
According to the FTC’s January 2015 complaint, the advertisements claimed that Jungle Rangers had “scientifically proven memory and attention brain training exercises, designed to improve focus, concentration and memory” and touted the game as giving children “the ability to focus, complete school work, homework, and to stay on task.” Focus Education’s website implied that these benefits would be permanent. The FTC charged Focus Education and its principals with misrepresenting the efficacy of their product and failing to have scientific evidence to support the claims made.
The final order settling the FTC’s complaint prohibits Focus Education and its principals from making the claims alleged in the complaint about the ifocus System or any substantially similar product unless the claims are non-misleading and are supported by competent and reliable scientific evidence.
The order also bars the respondents from making unsubstantiated claims about the benefits, performance, or efficacy of products or services that supposedly alter the brain’s structure or function, improve cognitive abilities, behavior, or academic performance, or treat or reduce the symptoms of cognitive disorders, including ADHD.
Finally, the order bars the respondents from misrepresenting the results of any test, study, or research; or misrepresenting that the benefits of a cognitive improvement product are scientifically proven.
The Commission vote to approve the final consent order and send letters to members of the public who submitted comments was 5-0. (FTC File No. 122-3153; the staff contact is Annette Soberats, Bureau of Consumer Protection, 202-326-2921)
The Federal Trade Commission works for consumers to prevent fraudulent, deceptive, and unfair business practices and to provide information to help spot, stop, and avoid them.
A PUBLICATION OF RANDOM U.S.GOVERNMENT PRESS RELEASES AND ARTICLES
Showing posts with label SCIENTIFIC EVIDENCE. Show all posts
Showing posts with label SCIENTIFIC EVIDENCE. Show all posts
Saturday, April 11, 2015
Tuesday, September 2, 2014
FINAL ORDER APPROVED BY FTC OVER DIETARY SUPPLEMENT'S MEMORY IMPROVEMENT CLAIMS
FROM: U.S. FEDERAL TRADE COMMISSION
FTC Approves Final Order Settling Charges that “BrainStrong Adult” Supplement Marketers Made Deceptive Memory Improvement Claims
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that supplement marketers i-Health, Inc. and Martek Biosciences made deceptive claims while advertising their BrainStrong Adult dietary supplement.
The FTC’s complaint against i-Health and Martek, announced in June 2014, charges that the two companies, which sold the supplement at major retail stores, including CVS Pharmacy, Walmart, Walgreens, and Rite Aid, as well as online through drugstore.com and Amazon.com falsely claimed that they had clinical proof that BrainStrong Adult improves adult memory.
The final order bars the companies from claiming that any dietary supplement, food, drug, or product promoted to prevent cognitive decline or improve memory or containing DHA can prevent cognitive decline or improve memory in adults, unless the claim is truthful and supported by clinical testing. It also bars the companies from making claims about the health benefits, performance, safety, or effectiveness of such products, unless the claims are supported by competent and reliable scientific evidence. Finally, the companies cannot claim they have clinical proof when they do not.
The Commission vote approving the administrative final order and responses to members of the public who submitted comments was 3-1-1, with Commissioner Maureen K. Ohlhausen voting no, and Commissioner Terrell McSweeny not participating. (FTC File No. 132-3067).
Subscribe to:
Posts (Atom)